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In drug discovery, the cerebrospinal ﬂuid (CSF) drug concentration (CCSF) has been used as a surrogate for
the interstitial ﬂuid (ISF) concentration (CISF). However, the CCSF-to-CISF gradient suggested for P-glyco-
protein (P-gp) substrates in rodents causes uncertainty in CISF estimations and subsequent
pharmacokinetic-pharmacodynamic analyses. To evaluate the utility of CCSF as a surrogate for CISF, this
study directly compared the CCSF with the CISF of 12 compounds, including P-gp substrates, under steady-
state conditions in wild-type and Mdr1a(/) rats using microdialysis coupled with cisternal CSF
sampling. In wild-type rats, the ISF-to-unbound plasma (Kp,uu,ISF) and CSF-to-unbound plasma (Kp,uu,CSF)
concentration ratios of the P-gp substrates, except for metoclopramide, were lower than those of the
non-P-gp substrates, and the Kp,uu,CSF values were within or close to 3-fold of the Kp,uu,ISF values for all the
compounds examined. The Kp,uu,CSF values of the selected P-gp substrates increased in Mdr1a(/) rats
with a similar magnitude to the Kp,uu,ISF values, resulting in the Kp,uu,CSF-to-Kp,uu,ISF ratios being un-
changed. These results suggested that P-gp-mediated active efﬂux at the bloodebrain barrier is a major
determinant not only for CISF, but also for CCSF, and that CCSF can be used as a surrogate for CISF even for P-
gp substrates in rats.
Copyright © 2015 The Authors. Published by Elsevier Ltd on behalf of The Japanese Society for the Study of
Xenobiotics. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
In drug discovery, understanding the relationship between the
pharmacokinetics and the pharmacodynamics of synthesized
compounds in animal pharmacological models is crucial forunder the plasma concen-
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Based on the “free drug hypothesis” [1], the unbound drug con-
centration in plasma (Cu,plasma) is frequently used for such at-
tempts; however, the Cu,plasma at pharmacologically effective dose
levels is not necessarily consistent with the in vitro effective con-
centration, particularly for central nervous system (CNS)-acting
compounds, because the Cu,plasma can overestimate unbound drug
concentrations in the brain (Cu,brain) because of the restrictive role
of the bloodebrain barrier (BBB). The BBB has highly developed
tight junctions and expresses active efﬂux transporters such as P-
glycoprotein (P-gp/ABCB1) [2], breast cancer resistance protein
(BCRP/ABCG2) [3], and multidrug resistance-associated protein 4
(MRP4/ABCC4) [4], thereby limiting drug CNS penetration. Com-
pounds with poor CNS penetration need higher doses to elicit their
pharmacological effects in the CNS, resulting in higher systemic
exposure and a narrower therapeutic index against peripheral
toxicities. Therefore, establishing methodologies to estimate thenese Society for the Study of Xenobiotics. This is an open access article under the CC
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in vivo pharmacological effects based on in vitro effective concen-
trations, as well as for optimizing the compound in terms of its
in vivo CNS penetration.
As unbound drugs in the brain interstitial ﬂuid (ISF) can directly
interact with the pharmacological targets in the CNS, measurement
or estimation of the drug ISF concentration (CISF) is required.
Microdialysis is the only method that can be used to assess CISF
directly, wherein a microdialysis probe is implanted in a brain re-
gion to supply and collect perfusate in equilibrium with unbound
drugs in the ISF [5]. This technique is useful for evaluating the CISF,
but it involves technical challenges and has a low throughput,
making it unsuitable for drug discovery settings. Instead, alterna-
tive approaches have been proposed, such as using the product of
the total drug concentration in the brain in vivo and the unbound
fraction in the brain (fu,brain) determined in vitro using brain ho-
mogenates [6] or brain slices [7], or using the cerebrospinal ﬂuid
(CSF) drug concentrations (CCSF).
The CCSF has been used as a surrogate for the CISF based on the
assumption of a rapid equilibrium between the ISF and CSF
compartments across the ependymal layer. Because of low protein
concentrations [8], the CCSF can be identical to the unbound drug
concentration in the CSF. One of the advantages of CSF sampling is
that this technique is applicable not only to nonclinical animal
species, but also to human subjects in clinical studies. This
advantage enables a direct comparison of CCSF between animals
and humans [8], which can be used to provide supportive evi-
dence to guide the efﬁcacious dose range to be tested in clinical
studies for CNS-acting drugs. Although the CCSF is considered to
be better than the Cu,plasma for predicting the CISF [6,9,10], the
utility of CCSF as a surrogate for CISF is still debatable, and the CCSF-
to-CISF gradient has been suggested for substrates of efﬂux
transporters, such as P-gp and BCRP, in rodents [8,11e13].
Therefore, an understanding of the capability and limitations of
CCSF as a surrogate for CISF has been a topic of interest. Recently,
we compared the CISF and the CCSF of 12 compounds, including P-
gp substrates, in cynomolgus monkeys and found that the CCSF
was within 3-fold of the CISF, even for P-gp substrates [14].
However, the impact of P-gp-mediated active efﬂux across the
BBB on the CISF and CCSF could not be directly evaluated in that
monkey study.
Recently, transporter-deﬁcient rats have been developed [15,16],
and these animal models are considered to be useful tools for
evaluating the impact of efﬂux transporters on drug CNS distribu-
tion [17]. In the pharmaceutical industry, rats are commonly used
for toxicology and pharmacokinetic studies. In vivo pharmacolog-
ical and behavioral models for CNS disorders have also been
developed using rats. The larger size of rats is one of their advan-
tages over mice, even for CNS drug discovery, as it allows for sur-
gical manipulation to develop pharmacological models and higher
resolutions in imaging studies. Therefore, to evaluate the utility of
CCSF as a surrogate for CISF in rats, this study directly compared the
CCSF with the CISF of 12 compounds, including P-gp substrates, at
steady-state conditions in wild-type rats using microdialysis
coupled with cisternal CSF sampling. Among the efﬂux transporters
expressed at the BBB, the present study focused on P-gp because P-
gp substrate liability is a major hurdle in CNS drug discovery. Six
selected compounds were then further evaluated in Mdr1a(/)
rats. Cu,brain was also determined as the product of the total drug
concentration in the brain and fu,brain obtained using the brain
homogenate method, or predicted fu,brain based on a pH partition-
ing model. This study demonstrated that the CCSF of the tested
compounds, including that of the P-gp substrates, was within or
close to a practically acceptable threshold of 3-fold the CISF value in
rats.2. Materials and methods
2.1. Chemicals
Antipyrine, carbamazepine, lamotrigine, metoclopramide hy-
drochloride, ondansetron hydrochloride dihydrate, propranolol
hydrochloride, quinidine hydrochloride, and verapamil hydro-
chloride were purchased from Sigma Aldrich (St. Louis, MO). Mid-
azolam and desloratadine were obtained fromWako Pure Chemical
Industries (Osaka, Japan) and LKT Laboratories (St Paul, MN),
respectively. Risperidone and paliperidone (9-hydroxyrisperidone)
were obtained from AK Scientiﬁc (Union City, CA). E2074 [18]
synthesized at the Eisai Tsukuba Research Laboratories (Ibaraki,
Japan) was used. All other reagents and solvents were of analytical
grade and were commercially available.
2.2. Animals
All the experimental protocols and procedures were approved
by the Institutional Animal Care and Use Committee of Eisai, and all
the animal experiments were conducted at an animal research fa-
cility of Eisai accredited by the Center for Accreditation of Labora-
tory Animal Care and Use, Japan Health Sciences Foundation. Male
SpragueeDawley wild-type and Mdr1a(/) rats (8e9 weeks old)
were purchased from Charles River Laboratories Japan (Kanagawa,
Japan) and SAGE Labs (Boyertown, PA), respectively. The animals
were maintained at 20 Ce26 C and a relative humidity of 40%e
70% on a 12-h lightedark cycle with free access to food and water.
All surgeries were performed under anesthesia, and all efforts were
made to minimize suffering.
2.3. Microdialysis
In vivo microdialysis was performed in awake, freely moving,
jugular vein and carotid artery-cannulated wild-type and
Mdr1a(/) rats. One to two days before dosing, C-I-4 micro-
dialysis probes (Eicom, Kyoto, Japan) with 5-mm (for hippocam-
pus) and 3-mm (for frontal cortex) regenerated cellulose
membranes (50-kDa molecular weight cutoff) were stereotaxically
implanted under pentobarbital anesthesia (50 mg/kg, i.p.) into the
frontal cortex (3.2 mm anterior, 0.8 mm lateral from bregma, and
4.5 mm ventral from dura) and hippocampus (5 mm posterior,
5 mm lateral from bregma, and 8 mm ventral from dura) [19],
respectively, and were ﬁxed to the skull using dental cement. On
the day of the experiment, the probe was perfused with Ringer
HEPES buffer at a ﬂow rate of 1.5 mL/min. One to 2 h after the pre-
perfusion, a cocktail of two or three compounds was infused via
the jugular vein following an intravenous loading dose. The infu-
sion rate and loading dose are given in Figs. 1 and 2. In this study,
cassette dosing was used to minimize the study period and the
number of animals that were used. Since some compounds tested
in this study were reported to be P-gp inhibitors (e.g., verapamil
and quinidine), the dose levels were optimized to maintain the
Cu,plasma equal to or less than the lower limit of the reported half-
maximal inhibitory concentrations for P-gp [20] at steady state,
thereby minimizing the risk of P-gp-mediated drug-drug in-
teractions at the BBB [21].
The microdialysis dialysate was serially collected from the
frontal cortex and hippocampus at 30-min intervals up to 4 h
postdosing. Blood was also serially collected at 1-h intervals up to
4 h postdosing via the carotid artery cannula to prepare the plasma
samples.
After the 4-h sampling, CSF was immediately collected by
cisternal puncture under isoﬂurane anesthesia (3% inhalation),
and the animals were then euthanized by exsanguination under
Fig. 1. Concentration-time proﬁles of antipyrine (A), carbamazepine (B), lamotrigine (C), midazolam (D), metoclopramide (E), ondansetron (F), E2074 (G), risperidone (H), verapamil
(I), quinidine (J), paliperidone (K), and desloratadine (L) in unbound plasma (Cu,plasma, open circles), ISF in brain cortex (CISF,Cx, closed triangles), and ISF in hippocampus (CISF,HIP,
open triangles) in wild-type rats after a constant intravenous infusion with an intravenous loading dose. The infusion rate (mg/h/kg) and loading dose (mg/kg) were as follows: 0.10
and 0.22 for antipyrine, 0.20 and 0.21 for carbamazepine, 0.050 and 0.89 for lamotrigine, 0.40 and 0.40 for midazolam, 1.0 and 0.80 for metoclopramide, 1.0 and 0.46 for
ondansetron, 0.40 and 0.33 for E2074, 1.0 and 0.70 for risperidone, 1.0 and 0.90 for verapamil, 5.0 and 8.0 for quinidine, 1.0 and 0.80 for paliperidone, and 5.0 and 5.0 for
desloratadine. Blood and dialysate samples were serially collected for up to 4 h. The ISF concentrations were obtained from dialysate concentrations corrected for microdialysis
probe recoveries (Supplemental Table 1). Each point represents the mean ± SEM of three to ﬁve animals.
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hippocampus contralateral to the microdialysis probe-implanted
side). The brain tissue samples were homogenized in distilled
water to prepare 20% homogenates (w/v) immediately before
use.2.4. Microdialysis probe recovery
The microdialysis probe recovery of the test compounds was
determined as described earlier [14], and the details are given in
Supplemental Table 1. Based on the probe recoveries, the concen-
tration of a test compound in ISF (CISF) from the frontal cortex
(CISF,Cx) or hippocampus (CISF,HIP) was calculated using the in vivo
dialysate concentration (Cdialysate) as follows:CISF;Cx or CISF;HIP ¼
Cdialysate
Recovery
Our pilot study conﬁrmed that the recovery values for antipy-
rine, lamotrigine, E2074, quinidine, risperidone, and verapamil in
wild-type rats were consistent with those in Mdr1a(/) rats for
both the brain cortex and hippocampus regions. Thus, the recovery
values of the test compounds obtained from wild-type rats were
used in this study.
2.5. Drug unbound fractions in rat plasma and brain tissues
The unbound fractions of the test compounds in rat plasma
(fu,plasma) and brain (fu,brain) for cortex (fu,brain,Cx) and hippocampus
Fig. 2. Concentration-time proﬁles of antipyrine (A), lamotrigine (B), E2074 (C), risperidone (D), verapamil (E), and quinidine (F) in unbound plasma (Cu,plasma, open circles), ISF in
brain cortex (CISF,Cx, closed triangles), and ISF in hippocampus (CISF,HIP, open triangles) in Mdr1a(/) rats after a constant intravenous infusion with an intravenous loading dose.
The infusion rate (mg/h/kg) and loading dose (mg/kg) were as follows: 0.10 and 0.22 for antipyrine, 0.050 and 0.89 for lamotrigine, 0.20 and 0.17 for E2074, 0.50 and 0.35 for
risperidone, 1.0 and 0.90 for verapamil, and 3.0 and 5.0 for quinidine. Blood and dialysate samples were serially collected from Mdr1a(/) rats for up to 4 h. The ISF concentrations
were obtained from dialysate concentrations corrected for microdialysis probe recoveries (Supplemental Table 1). Each point represents the mean ± SEM of three to four animals.
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previously [14]; the details are given in Table 1. The fu,plasma was
calculated as the receiver (phosphate buffered saline, PBS) side-to-
donor (plasma) side concentration ratio. The fu,brain,Cx and fu,brain,HIP
were calculated as follows [11]:
fu;brain;Cx or fu;brain;HIP ¼
1=D

1

fu0  1
þ 1=D
where D and fu0 represent the dilution factor (5-fold) used to pre-
pare 20% tissue homogenates and the unbound fraction (deter-
mined as the ratio of the drug concentration in PBS to that in 20%
brain tissue homogenate), respectively. According to our pre-
liminary experiments, no remarkable difference in the whole brain
homogenate binding of selected P-gp substrates was observed be-
tween wild-type and Mdr1a(/) rats, for which the fu,brain values
(mean of 3 determinations) of quinidine, risperidone, and verap-
amil were 0.0286, 0.0893, and 0.0176 in wild-type rats and 0.0342,
0.0931, and 0.0280 in Mdr1a(/) rats, respectively. Thus, the
fu,brain,Cx and fu,brain,HIP values obtained from wild-type rats were
used in this study.
2.6. Analytical procedure
Samples obtained from the microdialysis probe recovery, the
protein-binding assay, and the in vivo studies were mixed with
acetonitrile containing an internal standard (300 nM propranolol),followed by centrifugation. The resulting supernatant was ﬁltrated,
and an aliquot of the ﬁltrate was subjected to high-performance
liquid chromatography with tandem mass spectrometry analysis.
The analytical conditions were reported previously [14] except for
those for paliperidone, which was subjected to electrospray ioni-
zation in positive ion mode and was monitored at 427.4 > 207.4.2.7. Calculations
The brain-to-plasma total drug concentration ratio (Kp,brain) for
the brain cortex (Kp,brain,Cx) or hippocampus (Kp,brain,HIP) was ob-
tained by dividing the total concentration in the brain cortex
(Cbrain,Cx) or hippocampus (Cbrain,HIP) by the plasma total concen-
tration (Cplasma), respectively. The plasma unbound concentration
(Cu,plasma) was a product of Cplasma and fu,plasma. The unbound drug
concentrations in the brain cortex (Cu,Cx,homogenate) and hippo-
campus (Cu,HIP,homogenate), as determined using the brain tissue
homogenate method, were obtained from Cbrain,Cx and Cbrain,HIP
multiplied by fu,brain,Cx and fu,brain,HIP, respectively. The ISF-to-
plasma unbound concentration ratio (Kp,uu,ISF) for the brain cortex
(Kp,uu,ISF,Cx) or hippocampus (Kp,uu,ISF,HIP), the CSF-to-plasma un-
bound concentration ratio (Kp,uu,CSF), and the ratio of the brain
unbound concentration determined using the brain homogenate
method to the plasma unbound concentration (Kp,uu,brain) for the
brain cortex (Kp,uu,brain,Cx) or hippocampus (Kp,uu,brain,HIP) were
calculated as follows:
Table 1
Unbound fractions of test compounds in rat plasma, brain cortex and hippocampus
tissues.
Test Compounds Unbound fraction
fu,plasma fu,brain,Cx fu,brain,HIP
Antipyrine 0.942 ± 0.049 0.715 ± 0.048 0.691 ± 0.178
Carbamazepine 0.389 ± 0.013 0.158 ± 0.001 0.131 ± 0.015
Lamotrigine 0.527 ± 0.018 0.176 ± 0.008 0.145 ± 0.010
Midazolam 0.0696 ± 0.0003 0.0130 ± 0.0019 0.0160 ± 0.0027
Metoclopramide 0.818 ± 0.016 0.359 ± 0.037 0.397 ± 0.068
Ondansetron 0.421 ± 0.045 0.143 ± 0.013 0.139 ± 0.010
E2074 0.675 ± 0.009 0.0975 ± 0.0199 0.106 ± 0.012
Risperidone 0.126 ± 0.015 0.0492 ± 0.0068 0.0516 ± 0.0079
Verapamil 0.194 ± 0.025 0.0317 ± 0.0093 0.0305 ± 0.0087
Quinidine 0.527 ± 0.039 0.0284 ± 0.0081 0.0213 ± 0.0046
Pailperidone 0.211 ± 0.025 0.154 ± 0.018 0.132 ± 0.015
Desloratadine 0.193 ± 0.005 0.00892 ± 0.00108 0.00911 ± 0.00046
The unbound fractions of test compounds in rat plasma (fu,plasma), brain cortex
(fu,brain,Cx) and hippocampus (fu,brain,HIP) were determined using equilibrium dial-
ysis. The brain cortex and hippocampus tissues dissected from the brains of naïve
male wild-type rats were homogenized in distilled water to prepare 20% homoge-
nate (w/v). Blank plasma freshly prepared from rat blood was used. The concen-
trations of the compounds spiked into the plasma were as follows: 0.1 mg/mL for
carbamazepine, midazolam, metoclopramide, and E2074; 0.2 mg/mL for antipyrine
and ondansetron; 0.3 mg/mL for verapamil and paliperidone; 0.5 mg/mL for lamo-
trigine and risperidone; and 1 mg/mL for quinidine and desloratadine. The concen-
trations of the compounds spiked into the brain cortex and hippocampus
homogenates were as follows: 0.1 mg/mL for carbamazepine, midazolam, E2074,
risperidone, verapamil, and paliperidone; 0.2 mg/mL for antipyrine, metoclopra-
mide, and ondansetron; 1 mg/mL for lamotrigine and quinidine; and 2 mg/mL for
desloratadine. One hundred and 50 mL each of the matrices and PBS (pH7.4) were
added to the donor and the receiver sides of the dialysis chamber, respectively, and
the dialysis apparatus HTD 96b (HTDialysis, LLC., Gales Ferry, CT) was incubated at
37 C for 24 h. Each value represents the mean ± SEM of three to six animals.
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CISF;Cx or CISF;HIP
Cu;plasma
Kp;uu;CSF ¼
CCSF
Cu;plasma
Kp;uu;brain;Cx or Kp;uu;brain;HIP¼
Cu;Cx;homogenate or Cu;HIP;homogenate
Cu;plasma
3. Results
3.1. ISF, CSF, and brain distribution of test compounds in wild-type
rats
Eleven compounds that were characterized as non-P-gp sub-
strates (antipyrine, carbamazepine, lamotrigine, and midazolam;
corrected efﬂux ratio, CER< 2), weak P-gp substrates (metoclo-
pramide, ondansetron, and E2074; 2  CER< 3), or good P-gp
substrates (risperidone, verapamil, desloratadine, and quinidine;
3  CER) in our previous study [14] were selected. In addition,
paliperidone was also included as a good P-gp substrate [22] in the
present study.
The time proﬁles for the Cu,plasma, CISF,Cx, and CISF,HIP of the test
compounds in wild-type rats are shown in Fig. 1. Cu,plasma was
calculated as the product of the total plasma concentrations and
fu,plasma values (Table 1). As the plasma and ISF concentrations of all
the test compounds reached steady state within 4 h after the start
of infusion (Fig. 1), the Kp,uu,ISF,Cx and Kp,uu,ISF,HIP values (Table 2)
were determined at 4 h postdosing using the Cu,plasma, CISF,Cx, and
CISF,HIP values (Supplemental Table 2). The Kp,uu,ISF,Cx values rangedfrom 0.0180 (desloratadine) to 1.38 (antipyrine), which generally
agreed with the corresponding Kp,uu,ISF,HIP values ranging from
0.0617 (paliperidone) to 1.12 (antipyrine).
Cisternal CSF and brain cortex and hippocampus tissues as well
as plasma were collected immediately after the 4-h ISF sampling in
wild-type rats (Supplemental Table 3), at which time the Kp,uu,CSF,
Kp,brain,Cx, and Kp,brain,HIP values were determined (Table 2). The
Kp,uu,CSF values ranged from 0.0678 (quinidine) to 1.51 (midazolam).
The Kp,brain,Cx ranged from 0.227 (paliperidone) to 3.11 (mid-
azolam), which agreed with the corresponding Kp,brain,HIP values
ranging from 0.172 (paliperidone) to 3.17 (midazolam).
The unbound fractions of the test compounds in rat brain cortex
(fu,brain,Cx) and hippocampus (fu,brain,HIP) tissues were determined
by equilibrium dialysis (Table 1). No remarkable differences be-
tween the fu,brain,Cx and the fu,brain,HIP values were observed. Using
these unbound fractions, the unbound drug concentrations in the
brain cortex and hippocampus were calculated to estimate the
Kp,uu,brain,Cx and Kp,uu,brain,HIP values, respectively (Table 2). The
Kp,uu,brain,Cx values ranged from 0.0220 (quinidine) to 0.805
(metoclopramide), which agreed with the Kp,uu,brain,HIP values
ranging from 0.0165 (quinidine) to 0.807 (metoclopramide).
For the compounds for which data were available, the Kp,uu,ISF,
Kp,uu,CSF, Kp,brain, and Kp,uu,brain values determined in the present
study were close to or within the ranges of the respective values
reported for wild-type rats (Supplemental Table 4).
3.2. ISF, CSF, and brain distribution of test compounds in Mdr1a(/
) rats
For antipyrine, lamotrigine, E2074, risperidone, verapamil, and
quinidine, the CNS distributions were also investigated in
Mdr1a(/) rats, and the time proﬁles for Cu,plasma, CISF,Cx, and
CISF,HIP are shown in Fig. 2. As the plasma and ISF concentrations
reached steady state within 4 h after the start of infusion, the
Kp,uu,ISF,Cx and Kp,uu,ISF,HIP values were determined at 4 h postdosing
(Table 3). The Kp,uu,ISF,Cx values agreed with the corresponding
Kp,uu,ISF,HIP values, with smaller variations observed across the
compounds in Mdr1a(/) rats (Kp,uu,ISF,Cx, 0.438 to 0.941;
Kp,uu,ISF,HIP, 0.559 to 1.26) compared with the variations observed in
wild-type rats (Kp,uu,ISF,Cx, 0.0674 to 1.38; Kp,uu,ISF,HIP, 0.111 to 1.12).
Cisternal CSF and brain cortex and hippocampus tissues as well
as plasma were collected immediately after the 4-h ISF sampling in
Mdr1a(/) rats (Supplemental Table 5), at which time the
Kp,uu,CSF, Kp,brain,Cx, and Kp,brain,HIP values were determined (Table 3).
The Kp,uu,CSF values ranged from 0.611 (verapamil) to 1.02 (antipy-
rine). The Kp,brain,Cx and Kp,brain,HIP values showed large variations
across the compounds (Kp,brain,Cx, 0.868 to 23.6; Kp,brain,HIP, 0.816 to
22.2), but the corresponding Kp,uu,brain,Cx and Kp,uu,brain,HIP values
showed relatively smaller variations (0.646e1.75 and 0.488 to 1.69,
respectively) in Mdr1a(/) rats.
3.3. Comparison of CNS distribution of P-glycoprotein substrates
and nonsubstrates between wild-type and Mdr1a(/) rats
The Kp,uu,ISF,Cx, Kp,uu,ISF,HIP, Kp,uu,CSF, Kp,brain,Cx, and Kp,brain,HIP
values of antipyrine, lamotrigine, E2074, risperidone, verapamil,
and quinidine were compared betweenwild-type and Mdr1a(/)
rats (Fig. 3). The Kp,uu,ISF, Kp,uu,CSF, and Kp,brain values of antipyrine
(0.68- to 1.2-fold increase) and lamotrigine (1.2- to 1.4-fold in-
crease) were minimally affected by Mdr1a knockout, consistent
with previous ﬁndings demonstrating that these compounds are
non-P-gp substrates [14].
The CNS distributions of P-gp substrates (E2074, risperidone,
verapamil, and quinidine) in Mdr1a(/) rats were greater than
those in wild-type rats. The effects of the absence of Mdr1a on the
Table 2
ISF, CSF, and brain distribution of test compounds in wild-type rats.
Test compounds Wild-type rats
Kp,uu,ISF,Cx Kp,uu,ISF,HIP Kp,uu,CSF Kp,brain,Cx Kp,brain,HIP Kp,uu,brain,Cx Kp,uu,brain,HIP
Antipyrine 1.38 ± 0.08 1.12 ± 0.05 1.08 ± 0.02 0.774 ± 0.024 0.664 ± 0.027 0.587 ± 0.018 0.487 ± 0.020
Carbamazepine 0.643 ± 0.040 0.749 ± 0.073 0.915 ± 0.080 1.49 ± 0.15 1.49 ± 0.11 0.604 ± 0.060 0.502 ± 0.036
Lamotrigine 0.643 ± 0.059 0.666 ± 0.124 0.628 ± 0.103 1.43 ± 0.12 1.37 ± 0.12 0.478 ± 0.041 0.377 ± 0.032
Midazolam 0.652 ± 0.130 0.620 ± 0.094 1.51 ± 0.18 3.11 ± 0.18 3.17 ± 0.20 0.581 ± 0.033 0.728 ± 0.046
Metoclopramide 0.669 ± 0.100 0.713 ± 0.088 0.422 ± 0.013 1.83 ± 0.10 1.66 ± 0.14 0.805 ± 0.042 0.807 ± 0.067
Ondansetron 0.283 ± 0.024 0.391 ± 0.056 0.243 ± 0.018 1.43 ± 0.03 1.31 ± 0.05 0.486 ± 0.009 0.432 ± 0.017
E2074 0.178 ± 0.030 0.163 ± 0.023 0.169 ± 0.022 2.05 ± 0.12 2.06 ± 0.13 0.296 ± 0.018 0.323 ± 0.021
Risperidone 0.119 ± 0.021 0.163 ± 0.021 0.161 ± 0.016 0.286 ± 0.039 0.200 ± 0.016 0.112 ± 0.015 0.0820 ± 0.0064
Verapamil 0.0718 ± 0.0112 0.114 ± 0.023 0.172 ± 0.072 0.484 ± 0.079 0.404 ± 0.055 0.0791 ± 0.0129 0.0635 ± 0.0087
Quinidine 0.0674 ± 0.0067 0.111 ± 0.028 0.0678 ± 0.0125 0.408 ± 0.053 0.409 ± 0.005 0.0220 ± 0.0029 0.0165 ± 0.0002
Paliperidone 0.0600 ± 0.0092 0.0617 ± 0.0132 0.0890 ± 0.0230 0.227 ± 0.035 0.172 ± 0.027 0.166 ± 0.025 0.108 ± 0.017
Desloratadine 0.0180 ± 0.040 0.0754 ± 0.0211 0.0815 ± 0.0221 1.56 ± 0.19 1.55 ± 0.20 0.0722 ± 0.0088 0.0730 ± 0.0093
Kp,uu,ISF, Kp,brain, and Kp,uu,brain values in brain cortex (Kp,uu,ISF,Cx, Kp,brain,Cx, Kp,uu,brain,Cx) and hippocampus (Kp,uu,ISF,HIP, Kp,brain,HIP, and Kp,uu,brain,HIP) and Kp,uu,CSF values of test
compounds in wild-type rats were determined 4 h after the start of infusion. Each value represents mean ± SEM of three to ﬁve animals.
Table 3
ISF, CSF, and brain distribution of test compounds in Mdr1a(/) rats.
Test compounds Mdr1a(/) rats
Kp,uu,ISF,Cx Kp,uu,ISF,HIP Kp,uu,CSF Kp,brain,Cx Kp,brain,HIP Kp,uu,brain,Cx Kp,uu,brain,HIP
Antipyrine 0.941 ± 0.021 1.26 ± 0.17 1.02 ± 0.07 0.868 ± 0.012 0.816 ± 0.026 0.659 ± 0.009 0.599 ± 0.019
Lamotrigine 0.782 ± 0.011 0.766 ± 0.082 0.901 ± 0.059 1.93 ± 0.16 1.77 ± 0.12 0.646 ± 0.055 0.488 ± 0.032
E2074 0.462 ± 0.057 0.639 ± 0.080 0.621 ± 0.096 9.30 ± 0.94 9.30 ± 0.97 1.34 ± 0.14 1.46 ± 0.15
Risperidone 0.443 ± 0.055 0.732 ± 0.131 0.796 ± 0.053 2.83 ± 0.16 2.72 ± 0.16 1.04 ± 0.06 1.11 ± 0.06
Verapamil 0.438 ± 0.025 0.559 ± 0.088 0.611 ± 0.075 10.7 ± 0.9 10.7 ± 0.9 1.75 ± 0.15 1.69 ± 0.14
Quinidine 0.785 ± 0.206 1.23 ± 0.22 0.835 ± 0.058 23.6 ± 1.1 22.2 ± 1.4 1.27 ± 0.06 0.896 ± 0.057
Kp,uu,ISF, Kp,brain, and Kp,uu,brain values in brain cortex (Kp,uu,ISF,Cx, Kp,brain,Cx, Kp,uu,brain,Cx) and hippocampus (Kp,uu,ISF,HIP, Kp,brain,HIP, and Kp,uu,brain,HIP) and Kp,uu,CSF values of six
selected test compounds in Mdr1a(/) rats were determined 4 h after the start of infusion. Each value represents mean ± SEM of three to four animals.
Fig. 3. Mdr1a knockout (KO)/wild-type (WT) ratios for the Kp,uu,ISF, Kp,uu,CSF, and Kp,brain
values. The KO/WT ratio represents the ratio of the mean Kp,uu,ISF,Cx, Kp,uu,ISF,HIP,
Kp,uu,CSF, Kp,brain,Cx, or Kp,brain,HIP value of antipyrine, lamotrigine, E2074, risperidone,
verapamil, or quinidine in Mdr1a(/) rats to that in wild-type rats. The Kp,uu,ISF,
Kp,uu,CSF, and Kp,brain values were obtained from Tables 2 and 3. Open bars, Kp,uu,ISF,Cx;
closed bars, Kp,uu,ISF,HIP; dotted bars, Kp,uu,CSF; hatched bars, Kp,brain,Cx; horizontal stri-
ped bars, Kp,brain,HIP.
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the Kp,uu,ISF,Cx, Kp,uu,ISF,HIP, Kp,uu,CSF, Kp,brain,Cx, and Kp,brain,HIP values
being 2.6-fold, 3.9-fold, 3.7-fold, 4.5-fold, and 4.5-fold higher in
Mdr1a(/) rats than in wild-type rats, respectively. The Mdr1a
defect had a greater impact on the total drug concentration in the
brain than on the ISF or CSF concentrations, for good P-gp sub-
strates (risperidone, verapamil, and quinidine). The magnitude ofthe increase in the Kp,uu,ISF,Cx and Kp,uu,ISF,HIP values of risperidone
(3.7-fold and 4.5-fold, respectively), verapamil (6.1-fold and 4.9-
fold, respectively), and quinidine (12-fold and 11-fold, respec-
tively) by Mdr1a knockout was comparable to that in correspond-
ing Kp,uu,CSF values (4.9-fold for risperidone, 3.6-fold for verapamil,
and 12-fold for quinidine). Meanwhile, a more pronounced increase
was observed for the Kp,brain,Cx and Kp,brain,HIP values of risperidone
(9.9-fold and 14-fold, respectively), verapamil (22-fold and 26-fold,
respectively), and quinidine (58-fold and 54-fold, respectively).
3.4. Comparison of Kp,uu,ISF, Kp,uu,CSF, and Kp,uu,brain values in rats
In the present study, the parameters were considered to be
similar if the two values were within 3-fold. This 3-fold threshold
was chosen to allow for differences arising from random experi-
mental error and for actual differences that could be considered to
have little impact on pharmacological and pharmacokinetic con-
sequences in nonclinical studies [23].
In the brain cortex, the Kp,uu,ISF,Cx values showed a good agree-
ment with the Kp,uu,CSF values within a 3-fold difference with the
exception of desloratadine, for which the Kp,uu,CSF was 4.5-fold
higher than the Kp,uu,ISF,Cx in wild-type rats (Fig. 4A). In the hip-
pocampus, the Kp,uu,ISF,HIP values agreed with the Kp,uu,CSF values,
and the differences for all the test compounds were within 3-fold
(Fig. 4D).
The Kp,uu,ISF,Cx values generally agreed with the Kp,uu,brain,Cx
values, but the Kp,uu,brain,Cx values of quinidine and desloratadine in
wild-type rats and of verapamil in Mdr1a(/) rats were 0.25-fold,
3.1-fold, and 4.0-fold of the Kp,uu,ISF,Cx values, respectively (Fig. 4B).
Similarly, the Kp,uu,ISF,HIP values agreed with the Kp,uu,brain,HIP values
within a 3-fold difference with the exception of those for quinidine,
for which the Kp,uu,ISF,HIP value was 6.7-fold greater than the
Kp,uu,brain,HIP value in wild-type rats (Fig. 4E).
Fig. 4. Comparison of Kp,uu,ISF, Kp,uu,CSF, and Kp,uu,brain values in rats. Relationships between Kp,uu,ISF,Cx and Kp,uu,CSF (A), Kp,uu,ISF,Cx and Kp,uu,brain,Cx (B), Kp,uu,brain,Cx and Kp,uu,CSF (C),
Kp,uu,ISF,HIP and Kp,uu,CSF (D), Kp,uu,ISF,HIP and Kp,uu,brain,HIP (E), and Kp,uu,brain,HIP and Kp,uu,CSF (F). Each value is presented as the mean ± SEM of three to ﬁve animals, and the open and
closed circles represent the values in wild-type rats and Mdr1a(/) rats, respectively. The solid line passing through the origin represents the line of unity ± 3-fold (dashed lines). 1,
antipyrine; 2, carbamazepine; 3, lamotrigine; 4, midazolam; 5, metoclopramide; 6, ondansetron; 7, E2074; 8, risperidone; 9, verapamil; 10, quinidine; 11, paliperidone; 12,
desloratadine.
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Kp,uu,CSF values, and only quinidine had a Kp,uu,CSF value thatwas 3.1-
fold higher than the Kp,uu,brain,Cx value inwild-type rats (Fig. 4C). The
Kp,uu,brain,HIP values were within or close to 3-fold of the Kp,uu,CSF
values, and only quinidine had a Kp,uu,CSF value that was 4.1-fold
higher than the Kp,uu,brain,HIP value in wild-type rats (Fig. 4F).
The Kp,uu,ISF or Kp,uu,brain values were compared between the
brain cortex and hippocampus (Supplemental Fig. 1). No regional
differences in the Kp,uu,ISF and Kp,uu,brain values were observed
except for the values for desloratadine, for which the Kp,uu,ISF,HIP
valuewas 4.2-fold higher than the Kp,uu,ISF,Cx value inwild-type rats.
These results suggested that the brain cortex and the hippocampus
can be considered as being nearly identical in terms of drug dis-
tribution at steady states, even for P-gp substrates.
The present study determined the fu,brain values using brain
homogenates. The unbound volume of distribution in a rat brain
slice (Vu,brain) can be predicted by a pH partitioningmodel using the
fu,brain and pKa of a compound [24]. Based on the proposed model,
the Kp,uu,brain values were estimated in wild-type rats
(Supplemental Fig. 2). Because of trapping in acidic intracellular
compartments, the pH partitioningmodel produces lower Kp,uu,brain
values for basic compounds (e.g., quinidine) than the brain ho-
mogenate method, resulting in larger differences between Kp,uu,-
brain and Kp,uu,ISF or Kp,uu,CSF for good P-gp substrates.
3.5. Comparison of drug CNS distributions between rats and
cynomolgus monkeys
With the exception of paliperidone, we previously examined the
Kp,uu,ISF, Kp,uu,CSF, Kp,brain, and Kp,uu,brain values of the test compoundsat steady state in cynomolgus monkeys [14]. To evaluate species
differences in the CNS distributions, the Kp,uu,ISF, Kp,uu,CSF, Kp,uu,brain,
and Kp,brain values obtained in wild-type rats were compared with
those obtained in cynomolgus monkeys (Fig. 5).
The Kp,uu,ISF values in cynomolgusmonkeys tended to be slightly
overestimated, compared with the Kp,uu,ISF,Cx values in rats, but the
differences were within 3-fold except for that for desloratadine, for
which the Kp,uu,ISF value in cynomolgus monkeys was 3.4-fold
higher than that in rats (Fig. 5A). The Kp,uu,CSF values in cyn-
omolgus monkeys also tended to be slightly overestimated,
compared with the Kp,uu,CSF values in rats, but the differences were
within 3-fold except for that for E2074, for which the Kp,uu,CSF value
in cynomolgus monkeys was 4.3-fold higher than that in rats
(Fig. 5B). Meanwhile, the Kp,uu,brain values in cynomolgus monkeys
were overestimated by more than 3-fold of the Kp,uu,brain,Cx values
in rats for 4 of the 11 test compounds, all of which were P-gp
substrates (E2074, risperidone, quinidine, and desloratadine)
(Fig. 5D). This discrepancy was mainly attributable to higher Kp,brain
values in cynomolgus monkeys for E2074, risperidone, and
desloratadine (Fig. 5C), and their fu,plasma and fu,brain,Cx values
showed minimal species differences (Supplemental Fig. 3).
4. Discussions
To understand the effects of drug candidates on the CNS quan-
titatively, the monitoring of unbound drug concentrations in the
brain is indispensable. Although the CCSF is widely used as a sur-
rogate for the Cu,brain in CNS drug discovery, a CCSF-to-Cu,brain
gradient has been suggested for the substrates of efﬂux trans-
porters, such as P-gp, in rodents [11e13,25]. On the other hand, we
Fig. 5. Comparison of CNS distributions of test compounds between rats and cynomolgus monkeys. The Kp,uu,ISF (A), Kp,uu,CSF (B), Kp,brain (C), and Kp,uu,brain (D) values were compared
between wild-type rats and cynomolgus monkeys. Each point represents the mean ± SEM of three to ﬁve animals. The rat data were obtained from Table 2, and the data for the
cynomolgus monkeys were obtained from our previous study [14]. As the ISF and brain tissues were collected form the brain cortex in the cynomolgus monkey study, the Kp,uu,ISF,Cx
and Kp,uu,brain,Cx values in rats were used for this comparison. 1, antipyrine; 2, carbamazepine; 3, lamotrigine; 4, midazolam; 5, metoclopramide; 6, ondansetron; 7, E2074; 8,
risperidone; 9, verapamil; 10, quinidine; 11, desloratadine.
Y. Nagaya et al. / Drug Metabolism and Pharmacokinetics 31 (2016) 57e6664previously demonstrated that the CCSF-to-CISF gradient was less
pronounced in cynomolgus monkeys and that the CCSF can be used
as a surrogate for the CISF in monkeys, even for P-gp substrates [14].
The purpose of the present study was to investigate the utility of
CCSF as a surrogate for CISF in rats by using 12 compounds that
covered a wide range of P-gp substrate susceptibility.
The CCSF was compared with the CISF for the test compounds
under steady-state conditions in wild-type rats (Fig. 4). Consistent
with the results in cynomolgus monkeys [14], a CCSF-to-CISF
gradient was not overly evident, even for P-gp substrates, and the
CISF and CCSF of good P-gp substrates were lower than the Cu,plasma
(Table 2). The Kp,uu,CSF values tended to overestimate the Kp,uu,ISF,Cx
values slightly for good P-gp substrates (eg, desloratadine)
(Fig. 4A); however, the differences were within or close to 3-fold,
and the trend disappeared when it was compared with the
Kp,uu,ISF,HIP values (Fig. 4D). To investigate the impact of active efﬂux
by P-gp on the CCSF-to-CISF gradient, the Kp,uu,ISF and Kp,uu,CSF values
were determined in Mdr1a(/) rats. Along with an increase in the
Kp,uu,ISF values caused by the P-gp defect, the Kp,uu,CSF values of P-gp
substrates, such as E2074, risperidone, verapamil, and quinidine,
also increased in the Mdr1a(/) rats, compared with the values
for wild-type rats (Table 3). The magnitude of the difference in the
Kp,uu,CSF values between the wild-type and Mdr1a(/) rats was
similar to that for the Kp,uu,ISF values (Fig. 3). These results sup-
ported the idea that the CCSF is generally predictive of the CISFwithin or close to a 3-fold difference, even for P-gp substrates in
rats. However, caution needs to be exercised when the P-gp-
mediated transport activity is similar to or greater than that of
desloratadine (Kp,uu,CSF < 0.1 in wild-type rats). A high P-gp trans-
port activity may cause a high degree of uncertainty in estimating
the CISF when the CCSF is used as a surrogate. However, this issue is
unlikely to be a major point for practical CNS drug discovery set-
tings because such compounds could be screened out during
in vitro P-gp substrate liability assays. The present study also
showed that the Kp,uu,CSF value of midazolam (1.51) was greater
than unity, whereas the Kp,uu,ISF values (0.620e0.652) were lower
than unity. Although the underlying mechanism for these opposite
concentration gradients across the BBB (CISF < Cu,plasma) and BCSFB
(CCSF > Cu,plasma) remains unknown, the results for midazolam may
also draw attention to the use of CCSF as a surrogate for CISF.
As demonstrated in the present study, the Kp,uu,CSF values of P-gp
substrates are affected by the defect in P-gp. P-gp is expressed not
only at the BBB, but also at the blood-CSF barrier (BCSFB) in rats.
However, P-gp is localized to the cytoplasm or subapical region of
the choroid plexus epithelial cells [26], and the P-gp protein
expression level at the rat BCSFB has been reported to be consid-
erably lower than that at the BBB [27]. Therefore, our ﬁndings and
literature information cumulatively suggest that the role of P-gp, if
any, is negligible at the BCSFB, and that diffusion across the epen-
dymal layer followed by P-gp-mediated active efﬂux at the BBB has
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role in cynomolgus monkeys [14]. PK modeling may be a useful
approach to further support this idea [28].
In the present study, the Kp,uu,brain values were also determined
using a brain homogenate method (Fig. 4) and were estimated
using the pH partitioning model [24] (Supplemental Fig. 2). In
particular, when the Cu,brain was estimated as the product of the
in vivo Cbrain and the predicted fu,brain values in brain slices based on
the pH partitioning model, the difference between the Cu,brain and
the CISF increased, along with a reduction in the Kp,uu,brain values
(Supplemental Figs. 2A and 2C), and the CCSF-to-Cu,brain gradient
was more evident (Supplemental Figs. 2B and 2D). The underlying
mechanism causing such inconsistency between the Kp,uu,ISF and
Kp,uu,brain values for compounds that undergo extensive active
efﬂux at the BBB remains unknown; however, except for such
compounds, both methods (microdialysis and the product of the
in vivo Cbrain and the in vitro fu,brain values) provided similar esti-
mates for the Cu,brain, which were predictable from the CCSF in rats
within a 3-fold difference. Thus, the data presented in this
study should be helpful for performing pharmacokinetic-
pharmacodynamic analyses during CNS drug discovery.
Interestingly, we found that the impact of Mdr1a knockout on
the Kp,brain values was 3-folde5-fold greater than that on the
Kp,uu,ISF values for good P-gp substrates (risperidone, verapamil,
and quinidine) (Fig. 3). It appears that the difference in the
magnitude of the increase caused by the P-gp defect between the
Kp,uu,ISF and Kp,brain values was pronounced along with in vivo P-gp
transport activities. The following possibilities can be considered.
The Kp,uu,ISF values of the drugs with high P-gp transport activities,
which show very limited entry into the CNS, might be over-
estimated in wild-type rats because of the invasive process asso-
ciated with microdialysis probe implantation. Assuming the
negligible impact of probe implantation on Kp,uu,ISF values, the
inconsistency is attributable to the difference in the distribution
volume in the brain parenchymal cells against ISF. Our preliminary
experiments conﬁrmed that Mdr1a knockout had no or minimal
impact on binding in brain homogenates. The tissue binding
properties in intact brain parenchymal cells, including the drug
trapping capacity of lysosomes [24], might be affected in Mdr1a(/
) rats. Or, P-gp might limit drug entry to the parenchymal cells
from ISF compartment since P-gp is reportedly expressed in the
brain parenchyma, but to a much lesser extent compared with the
BBB [29]. A comparison of the brain slice uptakes of P-gp substrates
between wild-type and Mdr1a(/) rats may further under-
standing of the underlying mechanism.
In drug discovery, rodents are commonly used to evaluate drug
CNS penetration in vivo. However, species differences in drug CNS
penetration are frequently debated upon the extrapolation of ro-
dent data to primates when the test compounds are P-gp sub-
strates. To address this issue, we compared the Kp,uu,ISF, Kp,uu,CSF,
Kp,uu,brain, and Kp,brain values obtained from wild-type rats with
those we had previously determined in cynomolgus monkeys [14].
Although the Kp,uu,ISF and Kp,uu,CSF values of the P-gp substrates in
the cynomolgus monkeys were similar to or slightly higher than
those in the rats, the differences were within or close to 3-fold for
the test compounds (Fig. 5A and B). While the Kp,brain values in
cynomolgus monkeys were more than 3-fold of those obtained in
rats for 5 of the 11 test compounds, all the outliers were P-gp
substrates (Fig. 5C). This ﬁnding is consistent with the results of a
previous PET study in which the brain distribution of P-gp sub-
strates was greater in large animals than in rodents [30]. The
fu,plasma and fu,brain values could not account for the species differ-
ences (Supplemental Fig. 3), and the resulting Kp,uu,brain values in
the cynomolgus monkeys were also more than 3-fold of those in
the rats for 4 of the 11 compounds (Fig. 5D). These results suggestthat the drug distribution from the ISF to the brain parenchyma
might be greater in cynomolgus monkeys than in rats for P-gp
substrates, whereas no remarkable species differences are likely to
exist in the contribution of P-gp to drug efﬂux between rats and
cynomolgus monkeys, at least at the BBB. Thus, rats can be prac-
tically used to predict Kp,uu,ISF and Kp,uu,CSF values in cynomolgus
monkeys or potentially even in humans to within or close to a 3-
fold difference, even for P-gp substrates, because the P-gp protein
expression levels at the BBB are reportedly similar between cyn-
omolgus monkeys and humans [31].
In conclusion, this study directly compared the CCSF with the CISF
of 12 compounds that covered a wide range of P-gp substrate
susceptibility in rats. The Kp,uu,CSF values were within or close to a
practically acceptable threshold: 3-fold of the corresponding
Kp,uu,ISF values in the brain cortex and hippocampus. Moreover, the
magnitude of the increase in the Kp,uu,ISF values of the P-gp sub-
strates in Mdr1a(/) rats was similar to that for the Kp,uu,CSF
values. These results suggested that P-gp-mediated active efﬂux at
the BBB is a major determinant not only for the CISF, but also for the
CCSF, and that the CCSF can be used as a surrogate for the CISF even for
P-gp substrates in rats.
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